<DOC>
	<DOCNO>NCT00622726</DOCNO>
	<brief_summary>The purpose study determine efficacy additional advantage intravitreal bevacizumab treatment ROP Zone I Zone II Posterior .</brief_summary>
	<brief_title>Bevacizumab Eliminates Angiogenic Threat Retinopathy Prematurity</brief_title>
	<detailed_description>This phase 2 study assess anti-neovascularization activity intravitreal bevacizumab , determine regression neovascular vessel retinopathy prematurity ( ROP ) , neonates acute stage 3 ROP zone I posterior zone II plus disease . This study enrol 150 confirmed case vision threaten ROP definite plus disease [ range Early Treatment Retinopathy Prematurity , Cryotherapy Retinopathy Prematurity . This do controversy regard determine plus disease increase concern many infant treat whose ROP would spontaneously regress . Bevacizumab administer intravitreally use 0.625 mg ( 0.025 ml ) injection eye . There intent give additional dos unless recurrence vision threaten stage 3 ROP plus disease since disease self limited completion vascularization . Clinical response evidence ocular toxicity document retinal imaging system ( manufactured Clarity Medical Systems , Inc. ) take pre-injection , one week one month post injection , 6 month age ( 54 week postmenstrual age ) ( window 50 70 week PMA ) ( primary outcome ) 12 month age ( 80 week postmenstrual age ) ( window 75 100 week PMA ) ( structural documentation ) . Using retinal imaging system , fluorescein angiogram take possible document structural outcome great detail . No evidence systemic toxicity document appropriate clinical laboratory test .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Infants screen American Academy Ophthalmology , American Academy Pediatrics , American Association Pediatric Ophthalmology Strabismus guideline ( ≤1500 gram birth ≤30 week gestation ) develop Stage 3 ROP zone I posterior zone II . 2 . Informed Consent parent guardian . 1 . Infants congenital systemic anomaly congenital ocular abnormality . 2 . Infants treat conventional laser therapy problem medium clarity . Generally , blind external cryotherapy would utilize initial therapy infant would exclude study even medium clear subsequently . 3 . Informed Consent parent guardian refuse . This mean infant automatically receive laser therapy . Bevacizumab ( Avastin® ) treatment give outside Protocol . No data use infant without Informed Consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Weeks</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Vascular Endothelial Growth Factor</keyword>
	<keyword>Angiogenesis Inhibitor</keyword>
	<keyword>Premature infant</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Zone I Posterior Zone II ROP</keyword>
	<keyword>Aggressive Posterior ROP</keyword>
	<keyword>Stage 3 ROP</keyword>
	<keyword>Neonatal Intensive Care Unit</keyword>
</DOC>